Skip to main content
SpringerLink
Log in

Role of Autologous Stem Cell Transplantation in Multiple Myeloma

  • Chapter
Myeloma Therapy

Part of the book series: Contemporary Hematology ((CH))

  • 536 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301.

    PubMed  CAS  Google Scholar 

  2. Barlogie B, Alexanian R, Dicke KA et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869–872.

    PubMed  CAS  Google Scholar 

  3. Attal M, Harousseau JL, Stoppa AM et al. For the Intergroupe Français du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.

    Article  PubMed  CAS  Google Scholar 

  4. Child JA, Morgan GJ, Davies FE et al. Medical research council adult leukemia working party: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  PubMed  CAS  Google Scholar 

  5. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized trial. Blood 1998; 92: 3131–3136.

    PubMed  CAS  Google Scholar 

  6. Fermand JP, Katsahian S, Divine M et al. High-dose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Groupe Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233.

    Article  PubMed  CAS  Google Scholar 

  7. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.

    Article  PubMed  CAS  Google Scholar 

  8. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

    Article  PubMed  CAS  Google Scholar 

  9. Blade J, Rosinol L, Sureda A et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative groupe PETHEMA. Blood 2005; 106: 3755–3759.

    Article  PubMed  CAS  Google Scholar 

  10. Barlogie B, Kyle RA, Anderson KC et al. Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929–936.

    Article  PubMed  CAS  Google Scholar 

  11. Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278–4282.

    PubMed  CAS  Google Scholar 

  12. Kumar S, Lacy MQ, Dispenzieri A et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161–167.

    Article  PubMed  CAS  Google Scholar 

  13. Harousseau JL, Milpied N, Laporte JP et al. Double-intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 3131–3136.

    Google Scholar 

  14. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    PubMed  CAS  Google Scholar 

  15. Attal M, Harousseau JL, Facon T et al. Intergroupe Francophone du Myelome: Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

    Article  PubMed  CAS  Google Scholar 

  16. Cavo M, Tosi P, Zamagni E et al. Prospective randomized study of single compared with double autologous stem cell transplantation for multiple myeloma: Bologna 96 clinical study. J. Clin Oncol 2007; 25: 2434–2441.

    Article  PubMed  Google Scholar 

  17. Sonneveld P, Van Der Holt B, Segeren CM et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: Long-term follow-up of the Deutch Cooperative Group HOVaN 24 trial. Haematologica 2007; 92: 928–935.

    Article  PubMed  CAS  Google Scholar 

  18. Barlogie B, Tricot G, Rabmussen E et al. Total therapy 2 without thalidomide in comparison with total therapy 1: Role of intensified induction and post-transplantation consolidation therapies. Blood 2006; 107: 2633–2638.

    Article  PubMed  CAS  Google Scholar 

  19. Moreau P, Hullin C, Garban F et al. Tandem autologous stem cell transplantation in high risk de novo multiple myeloma: Final results of the prospective and randomized IFM 99-04 protocol. Blood 2006; 107: 397–403.

    Article  PubMed  CAS  Google Scholar 

  20. Rajkumar V, Blaad E, Vesole D et al. Phase III clinical trial of Thalidomide plus Dexamethasone compared with Dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436.

    Article  PubMed  CAS  Google Scholar 

  21. Cava M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39.

    Article  Google Scholar 

  22. Goldschmidt H, Sonneveld P, Breitkreuz I et al. HOVON 50/GMMG-HD3 trial: Phase III study on the effect of thalidomide combined with high-dose melphalan in myeloma patients up to 65 years. Blood 2005; 106: 128a (abstract).

    Google Scholar 

  23. Macro M, Divine M, Uzunban Y et al. Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: A randomized trial. Blood 2006; 108: 22a (abstract).

    Google Scholar 

  24. Jagannath S, Durie B, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–783.

    Article  PubMed  CAS  Google Scholar 

  25. Oakervee HE, PoHat R, Curry N et al. PAD combination therapy (PS34l, doxoru-bicin and dexamethasone) for untreated multiple myeloma. Br J Haematol 2005; 755–762.

    Google Scholar 

  26. Popat R, Oakervee HE, Curry N et al. Reduced dose PAD (PS 341, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 2005; 106: 717a (abstract).

    Article  Google Scholar 

  27. Harousseau JL, Attal M. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica 2006; 91: 1498–1505.

    PubMed  CAS  Google Scholar 

  28. Barlogie B, Tricot G, Rasmussen E et al. Total therapy incorporating Velcade into upfront management of multiple myeloma: Comparison with TT2+thalidomide. Blood 2005; 106: 337a (abstract).

    Google Scholar 

  29. Wang M, Delaballe K, Giralt S et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 2005; 106: 231a (abstract).

    Google Scholar 

  30. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 2005; 106: 4050–4053.

    Article  PubMed  CAS  Google Scholar 

  31. Attal M, Harousseau JL, Leyvras S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006: 15: 3289–3294.

    Article  Google Scholar 

  32. Spencer A, Prince M, Roberts AW et al. First analysis of the Australian leukaemia and lymphoma group trial of thalidomide and alternate day prednisone following autologous stem cell transplantation for patients with multiple myeloma. Blood 2006; 108: 22a (abstract).

    Google Scholar 

  33. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.

    Article  PubMed  CAS  Google Scholar 

  34. Siegel DS, Desikan KR, Nehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54.

    PubMed  CAS  Google Scholar 

  35. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.

    Article  PubMed  CAS  Google Scholar 

  36. Palumbo A, Triolo S, Argentin C. Dose intensive melphalan with stem-cell support is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253.

    PubMed  CAS  Google Scholar 

  37. Palumbo A, Bringhen S, Petrucci MT et al. Intermediate-dose Melphalan improves survival of myeloma patients aged 50–70: Results of a randomized controlled trial. Blood; 2004: 3052–3057.

    Google Scholar 

  38. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 2007; 370: 1209–1218

    Article  PubMed  CAS  Google Scholar 

  39. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  PubMed  CAS  Google Scholar 

  40. Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and renal failure. Leukemia 2000; 14: 1310–1313.

    Article  PubMed  CAS  Google Scholar 

  41. San Miguel J, Lahuerta JJ, Garcia-Sanz R et al. Are myeloma patients with renal failure candidate for autologous stem cell transplantation. Hematol J 2000; 1: 28–36.

    Article  CAS  Google Scholar 

  42. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 66–75.

    Google Scholar 

  43. Vesole D, Tricot G, Jagannath S et al. Autotransplant in multiple myeloma: What have we learned? Blood 1996; 88: 838–847.

    PubMed  CAS  Google Scholar 

  44. Facon T, Avet-Loiseau H, Guillerm G et al. Chromosome 13 abnormalities identified by Fish analysis and serum B2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566–1571.

    Article  PubMed  CAS  Google Scholar 

  45. Tricot G, Spencer T, Sawyer J et al. Predicting long-term (~5 years) event-free survival in multiple myeloma patients following planned tandem autotransplant. Br J Haematol 2002; 116: 211–217.

    Article  PubMed  Google Scholar 

  46. Shaughnessy J, Jacobson J, Sawyer J et al. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression. Blood 2003; 101: 3849–3856.

    Article  PubMed  CAS  Google Scholar 

  47. Fassas AT, Spencer T, Sawyer J et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041–1047.

    Article  PubMed  CAS  Google Scholar 

  48. Chang H, Sloan S, Li D et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125: 64–68.

    Article  PubMed  Google Scholar 

  49. Gertz M, Lacy MQ, Dispenzieri A et al. Clinical implications of t(11;14) (q13;q32), t(4;14) (p16.3;q32), and 17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840.

    Article  PubMed  CAS  Google Scholar 

  50. Jaksic W, Trudel S, Chang H et al. Clinical outcomes in t(4;14) multiple myeloma: A chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23: 7069–7073.

    Article  PubMed  CAS  Google Scholar 

  51. Chang H, Qi C, Yi QL et al. p53 gene deletion detected by fluorescence in situ hybridisation is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105: 358–360.

    Article  PubMed  CAS  Google Scholar 

  52. Avet-Loiseau H, Attal M, Moreau P et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489–3495.

    Article  PubMed  CAS  Google Scholar 

  53. Palumbo A, Bringhen S, Caravita T et al. Oral Melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367: 825–831.

    Article  PubMed  CAS  Google Scholar 

  54. Mateos MV, Hernandez JM, Gutierrez WC et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a mul-ticenter phase l/II study. Blood 2006, online.

    Google Scholar 

  55. Palumbo A, Falco P, Falcone A et al. Oral revlimid plus melphalan and prednisone for newly diagnosed multiple myeloma: Results of a multicenter phase l/II study. Blood 2006; online.

    Google Scholar 

  56. Lacy M, Gertz M, Dispenzieri A et al. Lenalidomide plus dexamethasone in newly diagnosed myeloma: Response to therapy, time to progression and survival Lancet 2006; 367: 825–831.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Hospitalier Universitaire Hotel-Dieu, Place Alexis Ricordeau, France

    Jean-Luc Harousseau

Authors
  1. Jean-Luc Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winship Cancer Institute, Emory University, B3307 Clifton Road, Atlanta, GA, 30322, USA

    Sagar Lonial MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Harousseau, JL. (2008). Role of Autologous Stem Cell Transplantation in Multiple Myeloma. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-564-0_6

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-82-4

  • Online ISBN: 978-1-59745-564-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation